Molecular Determinants of Acquired Clinical Resistance to Small Molecule Kinase Inhibitors in Non-Small-Cell Lung Cancer.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Erlotinib; Gefitinib
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 04 Feb 2016 Biomarkers information updated
- 24 Jul 2013 Planned end date changed from 1 Aug 2013 to 1 Aug 2014 as reported by ClinicalTrials.gov.
- 24 Jul 2012 Planned number of patients changed from 160 to 400 as reported by ClinicalTrials.gov.